Erythropoiesis stimulating agents, blood transf... [Am J Hematol. 2010] - PubMed

loading

Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. [Am J Hematol. 2010]
Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
Hess G, Nordyke RJ, Hill J, Hulnick S. Am J Hematol. 2010 Nov; 85(11):838-43.
Suboptimal hemoglobin levels: do they impact patients and their therapy? Audience responses. [Semin Oncol. 2000]
Suboptimal hemoglobin levels: do they impact patients and their therapy? Audience responses.
Ludwig H, Pecorelli S. Semin Oncol. 2000 Apr; 27(2 Suppl 4):18-9.
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin. [Cancer Treat Res. 2008]
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin.
McKoy JM, Tigue CC, Bennett CL. Cancer Treat Res. 2008; 140:235-51.
Review The role of erythropoiesis-stimulating agents in the treatment of anemia. [Am J Manag Care. 2010]
Review The role of erythropoiesis-stimulating agents in the treatment of anemia.
Fishbane S. Am J Manag Care. 2010 Mar; 16 Suppl Issues:S67-73.
Review Erythropoiesis-stimulating agents: favorable safety profile when used as indicated. [Strahlenther Onkol. 2008]
Review Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR, Dunst J, Vaupel P. Strahlenther Onkol. 2008 Mar; 184(3):121-36.

Erythropoiesis stimulating agents, blood transfusion, and the practice of medici...
Erythropoiesis stimulating agents, blood transfusion, and the practice of medicine.
Am J Hematol. 2010 Nov ;85(11):835-7. doi: 10.1002/ajh.21870.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed